[ad_1]
Medical technology and pharmaceutical companies are transitioning beyond biopharmaceuticals, medical devices and equipment to provide comprehensive patient care. The key is to support sustainable proactive, predictive and personalized care delivery and management. This involves achieving better results, improving the experience of patients and clinicians in the care pathway, reducing healthcare costs, eliminating inefficiencies in the workflow, and maximizing capabilities.
For relevance and difference, many medical technology and pharmaceutical companies have adopted digital technology. As healthcare companies strive to increase the value of their customers and partners, digitalization is now seen as the driving force behind this transformation.
With the availability of digital tools and technologies, the industry’s goal is to accelerate the use of healthcare data for process improvement, product development, and value proposition enhancement while finding new monetization models.
Successfully carry out digital transformation
Medical technology companies must always choose where to invest in R&D resources: prioritize the development of their core capabilities and solutions, or digital infrastructure and analytical capabilities. Although both are essential, not all companies have the funds or skill sets to do both to develop data management or analysis algorithms, or the partner ecosystem can use, collaborate, create and share together risk. In addition, these companies may not have experience in establishing governance and regulatory compliance structures to comply with regulations and use clinical data.
Developing and maintaining a digital ecosystem requires specific internal functions as well as planning and resources to realize the multiple benefits of data, analysis, and collaboration with appropriate partners. The platform provides a cloud-based ecosystem that enables secure access and data sharing among multiple stakeholders through digital tools and applications, and provides channels for cooperation between like-minded companies.
In this way, platform as a service (PaaS) allows users to take advantage of subscription-based data and cloud computing services without the need to build and maintain an infrastructure. It allows users to access, develop and run applications, and use a single platform to unify digital conversion, thereby reducing the use of resources required to promote conversion.
Max Milz, senior partner and senior vice president of Siemens Advanta Consulting, said: “Data is in an island, and in order to optimize clinical pathways, all stakeholders need to work together through co-creation and co-competition.” “In other words, it needs to be safe and secure. Access, process, store, analyze, and share data in a compliant manner to make it useful to different stakeholders. PaaS is one of the drivers of this integration. Medical technology companies can take advantage of the first mile of the hospital ecosystem Connect and last mile access to the data provided by the Teamplay digital medical platform to accelerate its digital transformation efforts.”
Medical technology requires a specific platform
Most healthcare data management use cases are industry-specific and require access to imaging, pathology, and clinical data. Stakeholders related to the platform can benefit from cooperation with a domain-specific platform that is incubated and managed by another experienced medical technology organization.
From the perspective of market access and connectivity, medical technology-specific platforms can provide vertical domain expertise, access to relevant data, specific applications of the department, and experience with security and regulatory compliance requirements. This allows partners to focus on the development and value proposition of their core solutions. Through the use of medical technology, PaaS provides flexibility for medical equipment and device companies to continuously adapt to changing market needs, optimize time and resource investment, and at the same time under the guidance of important partners with experience in developing suitable platforms guide.
In a highly competitive market, medical technology companies must focus on accelerating product development while collaborating with the best PaaS providers to help achieve their overall digital transformation goals.
Thomas Friese, senior vice president of digital platforms at Siemens Healthcare, explained: “Most medical technology companies have powerful products.” “However, they also need to transform into a sustainable service model.”
No need to do it separately. “Cooperation is becoming increasingly prominent in the fields of medical technology and pharmaceuticals, and all stakeholders can only benefit from integration. PaaS will become very relevant in this case, so that with its domain-specific expertise and digital transformation capabilities, it will The Teamplay digital medical platform is positioned as the only one.” Friese said.
A kind Proven and compliant PaaS platform: teamwork
A company with extensive experience in imaging and diagnosis can build a platform that combines a powerful diagnosis and treatment core with specialized digital products, and systematically expands it to multiple functions.
Several use cases can be used as templates for technological progress, enabling partners to achieve their goals. teamplay acts as a technology accelerator for medical technology companies, providing first-mile connections and last-mile access.
As a platform provider specific to medical technology, Siemens Healthineers provides vertical field expertise and industry expertise, which is different from the horizontal platform functions provided by leading IT companies. The subscription model also allows users to diversify their investments by letting partners take the lead and obtain higher returns. In general, Siemens Healthcare has a clear understanding of the right place with partners by improving fidelity and ease of use, while reducing the time and effort of partners.
Cooperation provides advantages for digital transformation
The advantages of cooperation in the creation of PaaS are obvious: this is a more strategic and long-term choice, and there are opportunities to collaborate, create and share risks together. Compared with building a platform, partners can provide scalability by optimizing time, resources, and investment. While establishing platforms with public cloud service providers, medical technology companies still need to network with hospitals for data access and arrange integration with equipment and healthcare IT ecosystems.
However, in cooperation with medical technology, PaaS is scalable in terms of access and connectivity, and the platform has the ability to develop by introducing new products, applications and vendors.
Medical technology companies must choose a partner whose vision, breadth and services should be aligned with the overall digital transformation efforts. Working with Siemens Healthineers provides access to a proven platform that is compliant, secure and acts as a technology accelerator. It further provides the potential to focus on core competencies while collaborating to explore new and adjacent opportunities.
The teamplay digital medical platform connects and integrates data from various sources across departments and agencies on a supplier, system, and equipment-neutral platform. It provides a scalable deployment model with hybrid computing capabilities, which combines cloud and edge deployment to meet specific use cases. Siemens Healthineers and its selected partner network also open access to innovations and solutions in AI and digital health, and provide opportunities to collaborate with peers and partners to achieve a risk-sharing model. By leveraging a secure platform infrastructure, it allows applications and algorithms to be deployed and operated on a global scale.
Most importantly, with Siemens Healthineers, medical technology companies have the opportunity to collaborate with the evolving platform and provide clinical credibility and business relevance.
Learn more about PaaS technology in healthcare.
This content was produced by Insights, the custom content department of MIT Technology Review. It was not written by the editors of MIT Technology Review.
[ad_2]
Source link






